OpenAI’s Fidji Simo Steps Down From AGI Deployment Role, Citing Health Challenges

Fidji Simo is leaving her full-time role as OpenAI’s chief executive of AGI deployment and will remain with the company as a part-time adviser, following a months-long medical leave prompted by a worsening chronic condition.

In a post on X on Thursday, Simo said she went on medical leave about three months ago after a severe flare-up of a neuroimmune illness she has lived with for seven years. “During that time, it became clear that the road to recovery would be much longer and more complex than I had anticipated and that I needed to focus on it fully,” she wrote.

Simo joined OpenAI’s board of directors in March 2024. The following year, CEO Sam Altman brought her into an executive role to oversee the company’s product and business organizations, allowing him to concentrate on research and OpenAI’s data centre buildout.

Before OpenAI, Simo was CEO of Instacart and, prior to that, headed the Facebook app at Meta. Her move into OpenAI’s AGI deployment role placed her at the centre of how the company brings its advanced AI systems to market.

Shortly before starting at OpenAI, Simo experienced a significant relapse of her health condition. She had been diagnosed in 2019 with postural tachycardia syndrome (POTS), a disorder that affects blood flow and can cause dizziness, rapid heartbeat, and fatigue, among other symptoms.

In an internal memo to OpenAI staff in April announcing her temporary leave, Simo explained that she had been putting off medical tests and new therapies to focus fully on work. “For my entire time here, I’ve postponed medical tests and new therapies to stay completely focused on the job and not miss a single day of work,” she wrote. “It’s now clear that I’ve pushed a little too far and I really need to try new interventions to stabilize my health.”

Her decision to step back from a full-time leadership position and remain as an adviser follows that period of leave and her reassessment of what her recovery requires.

Simo’s departure comes amid a broader reshaping of OpenAI’s leadership and product organization.

Around the time her medical leave became public, OpenAI saw a series of executive changes. Brad Lightcap, previously the company’s chief operating officer, moved into a role overseeing special projects. Greg Brockman, OpenAI’s president and cofounder, took over responsibility for product strategy.

Since Simo stepped back from her day-to-day role, OpenAI has reorganized its product teams further. The company has positioned Thibault Sottiaux as head of core products, a portfolio that includes ChatGPT.

These shifts align with OpenAI’s current strategy of concentrating on a smaller set of central offerings as it prepares for a planned initial public offering, which is now expected in 2027. Reports indicate the company is targeting a valuation of around $1 trillion.

As part of this tighter focus, OpenAI has:

• Merged teams working on ChatGPT, its AI-powered browser, and its AI coding agent to create what it describes as a unified “superapp.”
• Shut down more distant bets such as Sora.

The consolidation is intended to bring OpenAI’s main consumer and developer-facing tools closer together under a single product experience, while trimming projects that sit further from its core roadmap.

On the same day Simo publicly confirmed her transition to an advisory role, OpenAI announced a major upgrade to ChatGPT. The company introduced an AI agent within ChatGPT that can take actions on users’ behalf, such as moving local files and writing code, alongside a redesigned desktop app interface.

With this update, OpenAI is aiming to bring capabilities previously associated with its Codex system into the main ChatGPT experience, including helping users build bespoke software projects with AI assistance.

Simo’s shift from a full-time executive position to adviser status leaves OpenAI continuing to evolve its structure and product lineup while she focuses on long-term health treatment and recovery.